Henrike Maaß

Henrike Maaß

Auto-generated profile, based on publicly available information

Henrike Maaß

Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKatarzyna M. Sitnik
Katarzyna M. Sitnik
FKFran Krstanović
Fran Krstanović
NGNatascha Gödecke
Natascha Gödecke
URUlfert Rand
Ulfert Rand
TKTobias Kubsch
Tobias Kubsch
LCLuka Cicin-Sain
Luka Cicin-Sain
To date, no herpesvirus has been shown to latently persist in fibroblastic cells. Here, we show that murine cytomegalovirus, a β-herpesvirus, persists for the long term and across organs in PDGFRα-positive fibroblastic cells, with similar or higher genome loads than in the previously known sites of murine cytomegalovirus latency. Whereas murine cytomegalovirus gene transcription in PDGFRα-positive fibroblastic cells is almost completely silenced at 5 months post-infection, these cells give rise to reactivated virus ex vivo, arguing that they support latent murine cytomegalovirus infection. Notably, PDGFRα-positive fibroblastic cells also support productive virus replication during primary murine cytomegalovirus infection. Mechanistically, Stat1-deficiency promotes lytic infection but abolishes latent persistence of murine cytomegalovirus in PDGFRα-positive fibroblastic cells in vivo. In sum, fibroblastic cells have a dual role as a site of lytic murine cytomegalovirus replication and a reservoir of latent murine cytomegalovirus in vivo and STAT1 is required for murine cytomegalovirus latent persistence in vivo.

18 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNajat Bdeir
Najat Bdeir
TLTatjana Lüddecke
Tatjana Lüddecke
HMHenrike Maaß
Henrike Maaß
SSStefan Schmelz
Stefan Schmelz
URUlfert Rand
Ulfert Rand
LCLuka Cicin-Sain
Luka Cicin-Sain
The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.2. BA.2.86 and its JN.1 derivative evade neutralization by serum antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the immune escape of BA.2.86 and JN.1 via pseudovirus neutralization. Here we generate 33 BA.2.86 mutants, each reverting a single mutation back to BA.2. We use this library in an approach that we call reverse mutational scanning to define distinct neutralization titers against each epitope. Mutations within the receptor binding domain at K356T, V483Δ, and to a lesser extent N460K, A484K, and F486P enhance immune escape. Interestingly, 16insMPLF within the spike N-terminal domain and P621S within S1/S2 also significantly contribute to antibody escape of BA.2.86. Upon XBB.1.5 booster vaccination, neutralization titers against JN.1 and BA.2.86 improve considerably, and residual immune escape is driven by 16insMPLF, N460K, E554K, and to a lesser extent P621S, and A484K.

14 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MDMario Alberto Ynga Durand
Mario Alberto Ynga Durand
HMHenrike Maaß
Henrike Maaß
MMMarko Milošević
Marko Milošević
FKFran Krstanović
Fran Krstanović
MMMarina Pribanic Matesic
Marina Pribanic Matesic
LCLuka Cicin-Sain
Luka Cicin-Sain
While SARS-CoV-2 detection in sputum and swabs from the upper respiratory tract has been used as a diagnostic tool, virus quantification showed poor correlation to disease outcome and thus, poor prognostic value. Although the pulmonary compartment represents a relevant site for viral load analysis, limited data exploring the lower respiratory tract is available, and its association to clinical outcomes is relatively unknown. Using bronchoalveolar lavage (BAL) and serum samples, we quantified SARS-CoV-2 copy numbers in the pulmonary and systemic compartments of critically ill patients admitted to the intensive care unit of a COVID-19 referral hospital in Croatia during the second and third pandemic waves. Clinical data, including 30-day survival after ICU admission, were included. We found that elevated SARS-CoV-2 copy numbers in both BAL and serum samples were associated with fatal outcomes. Remarkably, the highest and earliest viral loads after initiation of mechanical ventilation support were increased in the non-survival group. Our results imply that viral loads in the lungs contribute to COVID-19 disease severity, while blood titers correlate with lung virus titers, albeit at a lower level. Moreover, they suggest that BAL SARS-CoV-2 copy number quantification at ICU admission may provide a predictive parameter of clinical COVID-19 outcomes.

10 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
HMHenrike Maass
Henrike Maass
IHImke Hinrichs
Imke Hinrichs
MPMartina Pavletic
Martina Pavletic
MHManuela Harries
Manuela Harries
TPTatjana Prinke
Tatjana Prinke
LCLuka Cicin-Sain
Luka Cicin-Sain
Background: While correlates of protection against symptomatic and severe breakthrough SARS-CoV-2 infections are well characterized, correlates of protection against virus transmission are incompletely understood. Methods: We studied a Croatian cohort of individuals with documented household exposure to SARS-CoV-2 in December 2022. Sera were acquired prior to symptom onset, at the time of the COVID-19 diagnosis of the index cases, and comprehensively analyzed for correlates of protection against virus transmission. We monitored participants for 14 days and tested them with PCR at the end of the observation period to identify any virus transmission, including asymptomatic ones. Interpretation: Out of nearly 200 tested serological parameters, 22 features were significantly different between the infected and the uninfected participants. Titers of variant-specific neutralizing antibody showed the biggest difference and were significantly higher in the uninfected subgroup. Some infected individuals with strong IgM responses to the spike antigen showed robust neutralization titers as well. Since IgM is likely an indication of recent antigenic exposure, data were reanalyzed by excluding such values. This refined analysis showed a complete segregation of infected and uninfected individuals into groups with low and high variant-specific neutralization titers. Therefore, our data indicate that high neutralizing titers are correlates of protection against SARS-CoV-2 transmission in intense contacts among household members. Funding: This research was funded by the Impulse and Networking fund of the Helmholtz Association through the grant PIE-0008 to LCS and VH-NG-19-28 to YCB and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy - EXC 2155 - project number 390874280 to LCS. BL and MH received funding within the RESPINOW project from the Federal Ministry of Education and Research under the grant number 031L0298A. Research in Context: Evidence before this study: Pre-existing immunity to SARS-CoV-2, whether from prior infections or vaccinations, has been shown to primarily protect against severe disease rather than preventing infection altogether. Many current studies examining this phenomenon focus on cohorts with breakthrough infections occurring a certain time after their last vaccination. However, these studies often lack precise information about when the individuals were infected and their serological status immediately before the infection. Added value of this study: Unlike other studies, we focused on a cohort of individuals with a confirmed SARS-CoV-2-positive household member. Serum samples were collected before symptom onset, coinciding with the COVID-19 diagnosis of the index cases. We analyzed various serum features to comprehensively assess their ability to protect not only against severe disease but also against virus transmission. Our findings revealed that individuals who remained uninfected had significantly higher concentrations of neutralizing antibodies compared to those who became infected. Implications of the available evidence: This finding suggests that neutralizing antibodies serve as a correlate of protection against virus transmission and could inform booster strategies based not on a fixed timeline but on antibody levels dropping below a specific threshold. However, due to the limited sample size of our study, larger studies are needed to confirm these results and establish an exact threshold.

16 April 2026 in Research Square
Verified
Preprint
Open access
RERoland Elling
Roland Elling
MEMiriam Eisner
Miriam Eisner
VKVivien Karl
Vivien Karl
FSFiona Seger
Fiona Seger
AWAnna Willems
Anna Willems
MHMaike Hofmann
Maike Hofmann
Background: Understanding how children mount effective antiviral immune responses is critical for preparedness against current and future emerging pathogens. Acute respiratory viral infections provide a tractable human model to dissect age-specific immunity, yet the integration of humoral, cellular, and mucosal responses in children remains incompletely defined. Insights into cross-reactive and durable immune mechanisms are essential to inform vaccination strategies and pandemic readiness. Methods: 182 participants (96 children, 86 adults) from 41 families with newly confirmed SARS-CoV-2 infection were enrolled in the prospective OMI-Kids study (DRKS00029155). Repeated PCR testing, symptom monitoring, saliva sampling, and blood collection 6–8 weeks post household infection enabled detailed immune profiling. Humoral and cellular responses, including neutralization against Hu-1, BA.2, and EG.5.1, as well as HLA-restricted CD8+ T cell responses, were analyzed across distinct immunity profiles. Cytokine autoantibodies were quantified using a multiplex bead-based IgG assay. Findings: Serum and salivary IgG and IgA levels correlated strongly, supporting saliva as a reliable, non-invasive proxy for immune monitoring in children. Antibodies elicited by Hu-1–based infection or vaccination showed partial cross-reactivity to BA.2 but failed to neutralize EG.5.1. Despite limited antibody breadth, T cell-mediated immunity was conserved across variants, with no major age-dependent differences in the magnitude, HLA breadth or functionality of virus-specific T cell responses. Conclusion: These findings highlight fundamental features of antiviral immunity in children, characterized by constrained antibody breadth but robust and conserved cellular responses in the context of SARS-CoV-2 evolution. Cross-reactive T cell immunity may represent a key mechanism of protection against severe disease despite ongoing viral evolution. This work establishes a framework for leveraging acute viral infections as a human model to inform immune protection, surveillance strategies, and vaccine design for future emerging pathogens.